Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
5.06
-0.16 (-3.07%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Monte Rosa Therapeutics stock have an average target of 14.33, with a low estimate of 10 and a high estimate of 17. The average target predicts an increase of 183.20% from the current stock price of 5.06.
Analyst Consensus: Buy
* Price targets were last updated on Mar 21, 2025.
Analyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $11 → $10 | Hold | Maintains | $11 → $10 | +97.63% | Mar 21, 2025 |
| Wedbush | Wedbush | Buy Maintains $15 → $17 | Buy | Maintains | $15 → $17 | +235.97% | Mar 21, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $14 → $11 | Buy → Hold | Downgrades | $14 → $11 | +117.39% | Dec 19, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +117.39% | Sep 12, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +235.97% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
67.58M
from 75.62M
Decreased by -10.64%
Revenue Next Year
48.96M
from 67.58M
Decreased by -27.55%
EPS This Year
-1.53
from -0.98
EPS Next Year
-1.64
from -1.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 120.8M | 180.6M | 270.9M | ||
| Avg | 67.6M | 49.0M | 95.7M | ||
| Low | 19.6M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.7% | 167.3% | 453.3% | ||
| Avg | -10.6% | -27.5% | 95.4% | ||
| Low | -74.1% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.72 | -0.70 | -0.30 | ||
| Avg | -1.53 | -1.64 | -1.37 | ||
| Low | -1.97 | -2.29 | -2.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.